Novartis Edges Out BMS In Japan With First-line Indication Approval For Tasigna Ahead Of Sprycel
This article was originally published in PharmAsia News
Executive Summary
TOKYO - The showdown between Novartis' Tasigna (nilotinib) and Bristol-Myer Squibb's Sprycel (dasatinib) for share of the chronic myeloid leukemia market has escalated in Japan as Tasigna received approval from Japan's Ministry of Health, Labor and Welfare Dec. 21 for first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia
You may also be interested in...
BMS Benefits From Focused Strategy, Novartis Looks To Vaccines; Abbott Tries To Educate U.S. Investors: Emerging Markets Earnings Roundup (Part 2)
Emerging markets remained a key focus of Big Pharma during first quarter earnings calls, with many highlighting exceptional growth in these markets, particularly China. Others talked at length about commercial strategy and sales force expansion, with some companies like Bristol-Myers Squibb Co. hyping the virtues of staying true to its innovative roots, while others like Novartis AG talked up the value of diversification. And Abbott Laboratories, in its continuing quest to "educate" U.S. investors about emerging markets, decided for a wholesale change in how it reports its business, although the initial reaction from at least one analyst might have caught the company off guard.
BMS Benefits From Focused Strategy, Novartis Looks To Vaccines; Abbott Tries To Educate U.S. Investors: Emerging Markets Earnings Roundup (Part 2)
Emerging markets remained a key focus of Big Pharma during first quarter earnings calls, with many highlighting exceptional growth in these markets, particularly China. Others talked at length about commercial strategy and sales force expansion, with some companies like Bristol-Myers Squibb Co. hyping the virtues of staying true to its innovative roots, while others like Novartis AG talked up the value of diversification. And Abbott Laboratories, in its continuing quest to "educate" U.S. investors about emerging markets, decided for a wholesale change in how it reports its business, although the initial reaction from at least one analyst might have caught the company off guard.
Otsuka Plans $2.8 Billion IPO To Feed Global Expansion
Otsuka Holdings Co., the parent of Japanese drug maker Otsuka Pharmaceutical Co. Ltd., has scheduled its long-planned initial public offering for December 15